Product approval information is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia (1). RiaSTAP is not indicated for dysfibrinogenemia.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/34VlPIV
No comments:
Post a Comment